Previous 10 | Next 10 |
home / stock / aplif / aplif news
2023-06-23 07:44:47 ET Appili Therapeutics press release ( OTCQB:APLIF ): FY GAAP EPS of -C$0.08. For further details see: Appili Therapeutics GAAP EPS of -C$0.08
Executed US$7.3M initial contract with U.S. Air Force Academy for ATI-1701 Upcoming PDUFA date of September 23, 2023 for ATI-1501 Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on dru...
Upcoming PDUFA date of September 23, 2023 Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Pat...
Funding will enable Appili to advance it’s Biodefense Vaccine Candidate ATI-1701 to IND NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “...
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will presen...
Accomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications Dr. Nabors representing Appili at the World Vaccine Congress in Washington, D.C. Appili Therapeutics Inc. (TSX: AP...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectiou...
Appili Therapeutics press release ( OTCQB:APLIF ): Q3 GAAP EPS of -$0.06. As of December 31, 2022, the Company had cash of $1.4 million, For further details see: Appili Therapeutics GAAP EPS of -$0.06
Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal yea...
Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmace...
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
Appili Therapeutics Inc Website:
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...